当前位置:首页 > 报告详情

罗氏 250113_roche_jpm.pdf

上传人: c** 编号:604008 2025-02-03 29页 2.06MB

1、Doing now what patients need nextThis presentation contains certain forward-looking statements.These forward-looking statements may be identified by words such as believes,expects,anticipates,projects,intends,should,seeks,estimates,future or similar expressions or by discussion of,among other things

2、,strategy,goals,plans or intentions.Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation,among others:1pricing and product initiatives of competitors;2legislative and regulatory developments and

3、economic conditions;3 delay or inability in obtaining regulatory approvals or bringing products to market;4 fluctuations in currency exchange rates and general financial market conditions;5 uncertainties in the discovery,development or marketing of new products or new uses of existing products,inclu

4、ding without limitation negative results of clinical trials or research projects,unexpected side-effects of pipeline or marketed products;6 increased government pricing pressures;7 interruptions in production;8 loss of or inability to obtain adequate protection for intellectual property rights;9 lit

5、igation;10 loss of key executives or other employees;and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roches earnings or earnings per share for this year or any subsequent period will nece

6、ssarily match or exceed the historical published earnings or earnings per share of Roche.For marketed products discussed in this presentation,please see full prescribing information on our website All mentioned trademarks are legally protected.Unlocking the next era of innovationTeresa GrahamCEO Roc

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了罗氏制药公司未来的发展战略和计划。主要内容包括: 1. 罗氏制药公司计划通过实施六项解决方案来提高研发效率,包括采用统一的药物组合框架、优化研发流程、改进组合管理、设定雄心勃勃的研发目标、与外部创新接轨以及引入“门槛”机制来识别具有变革潜力的资产。 2. 罗氏制药公司计划到2025年,在五大优先治疗领域(肿瘤学、免疫学、眼科、神经学和心血管/肾脏/代谢)推出20种变革性药物。 3. 罗氏制药公司计划通过合作伙伴关系和并购来补充其药物组合,包括在肿瘤学、免疫学、眼科、神经学和心血管/肾脏/代谢等领域的重要交易。 4. 罗氏制药公司预计其诊断业务将在2024年至2030年间实现中到高个位数的销售增长,而其制药业务将在2024年至2029年间实现增长。 5. 罗氏制药公司预计在2025年及以后将有重大新闻流和管道更新,包括12项关键的III期试验结果和多项新药的III期试验启动。
哪些药物正在推动罗氏制药近期至中期增长? 罗氏制药如何通过“The Bar”标准筛选创新药物? 罗氏制药2025年及以后有哪些重大药物研发新闻?
客服
商务合作
小程序
服务号
折叠